Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Köstenberger, M; Nahler, G; Jones, TM; Neuwersch, S; Likar, R.
The Role of Cannabis, Cannabidiol and Other Cannabinoids in Chronic Pain. The Perspective of Physicians.
J Neuroimmune Pharmacol. 2022; 17(1-2):318-333 Doi: 10.1007/s11481-021-10010-x
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Köstenberger Markus
Co-Autor*innen der Med Uni Graz
Likar Rudolf
Neuwersch-Sommeregger Stefan Matthias
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Currently, there is a renewed interest in treatments with medical cannabis and cannabinoids. Based on an increasing number of publications over the last decades that permitted new insights into mechanisms, efficacy and safety of cannabinoids, the use of cannabinergic medications is authorised in an increasing number of European and non-European countries. The alleviation of chronic, painful conditions is, since thousands of years, one of the primary reasons for the use of cannabis. Depending on the country, a wide range of medicinal cannabis preparations are available:ranging from defined cultivars of medical cannabis, mainly varying in their THC:CBD ratio, that are inhaled or taken as whole plant extracts,to highly purified single cannabinoids, such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD),or mixtures of two enriched extracts, standardised to a 1:1 ratio of THC:CBD (nabiximols). Although conflicting opinions continue to exist, the majority of reviews in the past concluded that medical cannabis and cannabinoids play a significant role in the management of pain. Surprisingly, systematic studies to date do not support an "entourage effect" of the other plant constituents of cannabis (mainly terpenoids) in treatment of chronic pain. An emerging cannabinoid is CBD which is the only cannabinergic medication available at present that does not cause the typical "cannabis high"; it is not a "controlled substance". However, despite years of research, there is either no study or no well-conducted, head-to-head, comparison available between different cannabis cultivars, between pure cannabinoids, and between pure cannabinoids and extracts. It remains unanswered which is the optimal treatment approach.
Find related publications in this database (using NLM MeSH Indexing)
Cannabis - administration & dosage
Cannabinoids - therapeutic use
Chronic Pain - drug therapy
Medical Marijuana - therapeutic use

Find related publications in this database (Keywords)
Cannabis
Cannabinoids
Cannabidiol
Delta-9-tetrahydrocannabinol
Opioids
© Med Uni Graz Impressum